市场消息：希音正就邀请博裕和瑞银作为基石投资者参与其IPO进行谈判。

Xiansheng Pharmaceutical on Aug. 20 said it has struck a strategic cooperation with Ruiyang (Shandong) Biopharmaceutical on the domestic Class-1 biologic new drug Kulaivebai mAb injection. Under the deal Xiansheng will hold exclusive commercialization rights in Greater China. The marketing authorisation application has been accepted by the National Medical Products Administration’s Center for Drug Evaluation (CDE) and placed in priority review. The company said the collaboration will strengthen its anti-infectives product portfolio.

As of end-June, Nanjing Bank's nonperforming loan ratio fell 0.01 ppt from end-2025 to 0.82%; provision coverage declined 7.51 ppt to 306.11%. 1H credit impairment losses increased 34.77% YoY. Independent director Qiang Ying told the 2026 interim briefing the YoY rise mainly reflected the bank’s decision to step up risk disposal and clean-up. The bank said it will continue a long-term, prudent, high-quality strategy to maintain an adequate risk buffer and moderate profitability; Qiang said she will take an active role in governance to oversee compliance, conflict-of-interest issues and protection of minority shareholders.